

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
24 November 2022 (24.11.2022)



(10) International Publication Number
WO 2022/246059 A1

(51) International Patent Classification:

A61K 31/438 (2006.01) A61P 25/28 (2006.01)
C07D 471/00 (2006.01)

(21) International Application Number:

PCT/US2022/030020

(22) International Filing Date:

19 May 2022 (19.05.2022)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/190,299 19 May 2021 (19.05.2021) US
63/192,398 24 May 2021 (24.05.2021) US
63/331,011 14 April 2022 (14.04.2022) US

(71) Applicant: AMYRIAD PHARMA, INC. [US/US]; 444 S. Flower St., Suite 1300, Los Angeles, California 90071 (US).

(72) Inventor: ROGERS, Sharon L.; c/o AMYRIAD PHARMA, INC., 444 S. Flower St., Suite 1300, Los Angeles, California 90071 (US).

(74) Agent: CAFFIN, Lee et al.; Cooley LLP, 1299 Pennsylvania Ave., Suite 700, Washington, District of Columbia 20004 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,

DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))
- as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))

Published:

- with international search report (Art. 21(3))

(54) Title: METHOD OF TREATING ALZHEIMER'S DISEASE




FIG.1

(57) Abstract: The present disclosure is directed to the treatment of Alzheimer's disease by administering 1',3'-dihydro-2H-spiro[imida zo[1,2a]pyridine-3,2'-inden]-2-one orally at a daily dose of 180mg as a single active agent or co-administered with donepezil hydrochloride and/or memantine hydrochloride.